Back to Results
First PageMeta Content
Prodrugs / Tamoxifen / Treatment of bipolar disorder / Breast cancer / Cancer / Endometrial cancer / Oncotype DX / Adjuvant therapy / Medicine / Alkenes / AstraZeneca


Embargoed for Release: 7:30 a.m. CT, Dec. 5, 2012 Media Contact: Jeremy Moore[removed]
Add to Reading List

Document Date: 2012-11-30 01:09:56


Open Document

File Size: 192,41 KB

Share Result on Facebook

City

SAN ANTONIO / Oxford / /

Company

AstraZeneca / /

Country

United Kingdom / /

Currency

pence / /

/

Facility

University of Oxford / The University of Texas Health Science Center / Baylor College of Medicine / Glasgow Caledonian University / /

IndustryTerm

Cancer Therapy / care for patients with breast cancer / /

MedicalCondition

uterine cancer / node-positive disease / Uterine cancer K-Ms / early breast cancer / approximately halving breast cancer / ER+ disease / percent lower breast cancer / translational and clinical cancer / primary cancer / endometrial cancer / positive breast cancer / Cancer Research U.K / breast cancer / ER-positive breast cancer / /

Organization

Epidemiological Studies Unit / Glasgow Caledonian University / Glasgow / U.K. Medical Research Council / Baylor College of Medicine / Clinical Trial Service Unit / United States Army / Cancer Therapy & Research Center / European Union / American Association for Cancer Research / University of Texas Health Science Center at San Antonio / University of Oxford / 1Clinical Trial Service Unit / /

Person

Christina Davies / Jeremy Moore / /

/

Position

coordinator / /

PublishedMedium

Cancer Research / /

Technology

treating cancer / /

URL

www.sabcs.org / /

SocialTag